Content

Welcome to the CJU website » LOG IN

Details

Cancer immunotherapy for prostate cancer
Tjoa A. B.; Erickson J. S.; Bowes A. V.; Salgaller L. M.; Lodge A. P.; McLean G. J.; Ragde H.; Kenny M. G.; Boynton L. A.; Murphy P. G.;
Jun 1997 (Vol. 4, Issue 21, Pages( 79 - 82)

    Abstract

    Text-Size + 

  • Our approach to prostate cancer immunotherapy involves two components dendritic cells as antigen-presenting cells; and the antigen used to target T-cell attack, HLA-A0201-associated peptides from prostate specific membrane antigen (PSMA). We have conducted a phase I dose-ranging study in 51 men with advanced prostate cancer, using dendritic cells pulsed with a PSMA peptide. no significant toxicity was observed. In that study, T-cell response was enhanced, with seven men meeting NCPC and PSA criteria for partial response. We are now conducting a phase II study with 67 men, who will receive 6 infusions of dendritic cells that have been pulsed with 2 PSMA peptides, at 6-week intervals. The phase II study design and rationale is described in this paper.

Current Issue

Feb 2017, Vol.24 No.1
canadian journal of urology mobile

canadian journal of urology